» Articles » PMID: 12164382

Uptake of Cationzied Albumin Coupled Liposomes by Cultured Porcine Brain Microvessel Endothelial Cells and Intact Brain Capillaries

Overview
Journal J Drug Target
Publisher Informa Healthcare
Date 2002 Aug 8
PMID 12164382
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The suitability of protein-coupled liposomes as drug carriers for brain specific targeting was investigated using albumin (BSA) and cationized albumin (CBSA), respectively, as model proteins. Liposomes coated with polyethylene glycol (sterically stabilized, PEG-liposomes) were prepared from phosphatidylcholine, cholesterol, and a PEG-derivatized phospholipid and covalently coupled to thiolated BSA or CBSA. Liposomes were loaded with carboxy-fluorescein and rhodamine-labeled dipalmitoyl-phosphatidylethanolamine as hydrophilic and lipophilic marker compounds, respectively. The interaction of these constructs with monolayers of porcine brain capillary endothelial cells (BCEC) and freshly isolated porcine brain capillaries was studied by means of fluorescence assays and confocal laser scanning fluorescence microscopy (CLSFM). In contrast to BSA, CBSA was rapidly taken up by cultured BCECs. BSA-coupled liposomes did not interact with endothelial cells, whereas CBSA-coupled liposomes bound to cellular surfaces and exhibited time dependently a high intracellular accumulation. CBSA-conjugated liposomes were also taken up by intact brain capillaries. Cellular uptake could be inhibited by free cationized albumin, phenylarsineoxide, nocodazole, and filipin, but not by dansylcadaverine, suggesting a caveolae-mediated incorporation process. Immunostaining demonstrated a high expression of caveolin in the capillary endothelium. In conclusion, liposomes coupled to CBSA are taken up into brain endothelium via an endocytotic pathway and may therefore be a suitable carrier for drug delivery to the brain.

Citing Articles

Liposomes for the Treatment of Brain Cancer-A Review.

Raju R, Abuwatfa W, Pitt W, Husseini G Pharmaceuticals (Basel). 2023; 16(8).

PMID: 37630971 PMC: 10458450. DOI: 10.3390/ph16081056.


Nanoparticle-Based Drug Delivery Systems: An Inspiring Therapeutic Strategy for Neurodegenerative Diseases.

Duan L, Li X, Ji R, Hao Z, Kong M, Wen X Polymers (Basel). 2023; 15(9).

PMID: 37177342 PMC: 10181407. DOI: 10.3390/polym15092196.


Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB.

Satapathy M, Yen T, Jan J, Tang R, Wang J, Taliyan R Pharmaceutics. 2021; 13(8).

PMID: 34452143 PMC: 8402065. DOI: 10.3390/pharmaceutics13081183.


Neuroinvasiveness of the MR766 strain of Zika virus in IFNAR-/- mice maps to prM residues conserved amongst African genotype viruses.

Nakayama E, Kato F, Tajima S, Ogawa S, Yan K, Takahashi K PLoS Pathog. 2021; 17(7):e1009788.

PMID: 34310650 PMC: 8341709. DOI: 10.1371/journal.ppat.1009788.


Key for crossing the BBB with nanoparticles: the rational design.

Lombardo S, Schneider M, Tureli A, Gunday Tureli N Beilstein J Nanotechnol. 2020; 11:866-883.

PMID: 32551212 PMC: 7277618. DOI: 10.3762/bjnano.11.72.